Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

February’s top stories: 60% of trial results not shared, Dilaforette-AGU team-up

Yale School of Medicine researchers revealed about 60% of academic clinical trial results were not shared after completion, and Dilaforette and Arabian Gulf University were to collaborate on a Phase II proof-of-concept trial of sevuparin in patients with sickle cell disease. Drugdevelopment-technology.com wraps-up the key headlines from February.

Download our 2018 Technology, Media & Telecoms Predictions worth over $5,000 for free


Go Top